An Open-Label, Single-Arm, Multicenter, Phase IV Study to Evaluate the Response to Treatment and Safety of Flexible Dose Treatment With Extended-Release Paliperidone in Patients With Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2013
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 01 Dec 2011 Actual patients number (84) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 01 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.